A clinician's perspective on liraglutide in clinical practice

Journal of Association of Physicians of India

Volumn 58, Issue SPEC. ISSUE, 2010, Pages 29-30

  Tandon, N ^a   John, M ^b   Sharma, S K ^c   Kesavadev, Jothydev ^d   Ganapathi, B ^e  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b KERALA INSTITUTE OF MEDICAL SCIENCES   (India)

^c MG Medical College Jaipur   (India)

^d Jothydev's Diabetes and Research Center   (India)

^e ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955824441     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Peterson GE. A checklist approach to selecting the optimal treatment regimen for a patient with type 2 diabetes. J Fam Pract 2009;58(9 Suppl Treating):S21-5.
2. Treating patients with type 2 diabetes: what is after lifestyle management and metformin? A focus on the glucagon-like peptide-1 receptor agonists. J Fam Pract 2009;58(9 Suppl Treating):S19-20.
3. McGill JB. Selecting among ADA/EASD tier 1 and tier 2 treatment options. J Fam Pract 2009;58(9 Suppl Treating):S26-34.
4. Pollom RD. Importance of daily plasma glucose control in type 2 diabetes. J Fam Pract 2009;58(8 Suppl):S10-7.
5. Haines ST. Patient education and monitoring recommendations for the use of glucagon-like peptide-1 receptor agonists. J Fam Pract 2009;58(9 Suppl Treating):S44-8.
6. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010;33:428-33.
7. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
8. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
9. McGill JB. Insights from the Liraglutide Clinical Development Program-- the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med 2009;121:16-25.
10. Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD) Trial. Expert Rev Endocrinol Metab 2009;4:119-29.
11. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-9.
12. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009;297:137-40.
13. Victoza® (liraglutide) Summary of Product Characteristics, July 2009. Available at: http://emc.medicines.org.uk/medicine/21986/SPC/Victoza+6+mg+ml+solution+for+injection+in+pre-filled+pen/. Accessed 09 July 2009.
14. Victoza® (liraglutide [rDNA origin] injection), solution for subcutaneous use Initial U.S. Approval: 2010. Label approved by FDA, NDA no. 022341. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf.
15. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33:1014-29.
16. Funnell MM, Brown TL, Childs BP, Haas LB, Hosey GM, Jensen B, et al. National standards for diabetes self-management education. Diabetes Care 2009;32 Suppl 1:S87-94.